Healthcare [ 3/11 ] | Biotechnology [ 47/148 ]
DK | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 5, 23 | 2.35 Increased by +260.96% | 2.68 Decreased by -12.31% |
| Apr 27, 23 | -1.98 Increased by +10.41% | -2.66 Increased by +25.56% |
| Feb 16, 23 | -3.70 Decreased by -97.86% | -2.56 Decreased by -44.53% |
| Nov 2, 22 | -3.03 Decreased by -106.12% | -2.49 Decreased by -21.69% |
| Aug 10, 22 | -1.46 Increased by +41.60% | -2.13 Increased by +31.46% |
| May 11, 22 | -2.21 Decreased by -88.89% | -2.00 Decreased by -10.50% |
| Mar 2, 22 | -1.87 Increased by +29.17% | -2.34 Increased by +20.09% |
| Nov 10, 21 | -1.47 Increased by +36.36% | -2.29 Increased by +35.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 47.39 M Increased by +669.37% | -121.43 M Decreased by -49.33% | Decreased by -256.23% Increased by +80.59% |
| Mar 31, 23 | 33.59 M Increased by +391.93% | -110.91 M Increased by +11.62% | Decreased by -330.21% Increased by +82.03% |
| Dec 31, 22 | 22.90 M Increased by +367.55% | -207.42 M Decreased by -95.56% | Decreased by -905.91% Increased by +58.17% |
| Sep 30, 22 | 15.29 M Increased by +1.27 K% | -168.96 M Decreased by -110.28% | Decreased by -1.11 K% Increased by +84.69% |
| Jun 30, 22 | 6.16 M Increased by +502.74% | -81.32 M Increased by +39.48% | Decreased by -1.32 K% Increased by +89.96% |
| Mar 31, 22 | 6.83 M Increased by +815.28% | -125.50 M Decreased by -99.86% | Decreased by -1.84 K% Increased by +78.16% |
| Dec 31, 21 | 4.90 M Increased by +815.33% | -106.06 M Increased by +23.68% | Decreased by -2.17 K% Increased by +91.66% |
| Sep 30, 21 | 1.11 M Decreased by -59.63% | -80.35 M Increased by +34.00% | Decreased by -7.22 K% Decreased by -63.49% |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.